ijNr

Review Article

Pharmacological Approaches to Colic Pain: Mechanistic Insights and Clinical Evidence on Camylofin-Diclofenac Therapy

Devesh Kumar[1], Archna Khurana[2]

[1]IR Innovate Research Private Limited, Noida, Uttar Pradesh, India, [2]Department of Clinical Research, Texila American University, Coimbatore, Tamil Nadu, India

Abstract

Colic pain, often characterized by intermittent abdominal cramps due to smooth muscle contractions, is a common symptom of various gastrointestinal (GI) disorders such as irritable bowel syndrome (IBS) and functional abdominal pain. Effective management typically involves pharmacological therapies targeting either muscle spasm or inflammation. Camylofin, an antispasmodic, and Diclofenac, a nonsteroidal anti-inflammatory drug, represent two key classes of drugs utilized in colic pain management. Camylofin works by blocking calcium ion influx and inhibiting muscarinic receptors, reducing smooth muscle spasms. Diclofenac, through the inhibition of cyclooxygenase enzymes, reduces prostaglandin production, alleviating pain and inflammation. Combining these drugs targets both the muscular and inflammatory components of colic pain, potentially offering a more comprehensive approach to symptom relief. Clinical evidence suggests that the Camylofin-Diclofenac combination is effective in reducing pain and improving quality of life in patients with colic-related disorders, including IBS. While the therapy demonstrates a favorable safety profile in the short term, potential risks such as GI, renal, and cardiovascular side effects should be carefully considered, especially with prolonged use. Further research is required to optimize dosing regimens, evaluate long-term safety, and explore personalized treatment strategies. This review aims to provide a comprehensive overview of the mechanistic insights and clinical evidence supporting the use of Camylofin-Diclofenac combination therapy in managing colic pain.

Keywords: Camylofin-Diclofenac therapy, clinical evidence, and colic pain

Introduction to Colic Pain and its Treatment

Colic pain, characterized by intense abdominal discomfort or cramping, is a prevalent condition that affects millions globally. It is often linked to the gastrointestinal (GI) tract and is frequently encountered in conditions such as irritable bowel syndrome (IBS),[1] GI disorders,[2] and functional abdominal pain syndromes. Colic pain can be debilitating, leading to significant reductions in quality of life and productivity. It is described as intermittent, cramping pain that results from the contraction of smooth muscles in the intestines or other parts of the digestive tract.[3]

The exact etiology of colic pain varies, but it is frequently related to dysmotility, where the normal rhythm of muscle contractions within the GI tract is disrupted.[4] Various triggers, including stress, inflammation, altered gut microbiota, and food intolerances, contribute to its manifestation. The pain may be associated with bloating, distension, and changes in bowel movements.[5]

Pharmacological treatments are central to managing colic pain.[6] The primary aim of therapy is to reduce the intensity of pain and relieve the underlying causes, which may include smooth muscle spasm, inflammation, and motility disturbances. Drugs are typically grouped into two major classes: Antispasmodics and non-steroidal anti-inflammatory drugs (NSAIDs).[7,8]

Date of Submission: 21-01-2025
Date of Revision: 17-02-2025
Date of Acceptance: 04-03-2025

Access this article online
Website: https://innovationaljournals.com/index.php/ijnr
ISSN No: 2456-1320
DOI: 10.31690/ijnr.2025.v011i01.004

Address for Correspondence:
Dr. Archna Khurana, Department of Clinical Research, Texila American University, Module 310, III Floor, TIDEL Park, ELCOT-SEZ, Aerodrome Post, Coimbatore-641014, Tamil Nadu, India. E-mail: archnakhurana193@gmail.com

This review focuses on the pharmacological combination of Camylofin, an antispasmodic, and Diclofenac, an NSAID, which has shown potential in managing colic pain. The review will delve into the mechanisms of action of these drugs, the rationale for combining them, and the clinical evidence supporting their efficacy and safety in treating colic pain.

Mechanisms of Colic Pain and Current Pharmacological Strategies

Pathophysiology of colic pain

Colic pain arises primarily from abnormal motility and smooth muscle contractions within the GI tract.[9] The underlying mechanisms involve a combination of visceral hypersensitivity[10] (increased pain perception), intestinal motility disturbances, and inflammation. In response to certain stimuli, such as stress, food triggers, or hormonal fluctuations, the GI tract can undergo spasms or dysregulated motility, leading to the sensation of pain.

At a molecular level, several factors contribute to colic pain, including the activation of smooth muscle cells, the release of neurotransmitters, and the stimulation of pain receptors in the gut. Key mediators include:

- Acetylcholine (involved in smooth muscle contraction)
- Serotonin (regulates motility and sensation)
- Substance P (a pain neurotransmitter)
- Calcitonin gene-related peptide (associated with pain signaling).

An understanding of these underlying mechanisms has led to the development of pharmacological agents that target specific components, such as muscle relaxation and inflammation control.[11]

Pharmacological approaches

At present, two primary classes of drugs are used in managing colic pain:

Antispasmodics: These drugs aim to relax smooth muscles and relieve spasm-induced pain.[12]

Camylofin is one such agent that directly targets the muscle contraction mechanism, providing relief from the painful spasms seen in colic pain.

NSAIDs: These drugs target inflammation as a contributor to colic pain. Diclofenac, a well-known NSAID, inhibits cyclooxygenase enzymes (COX-1 and COX-2), which are responsible for producing prostaglandins that mediate pain and inflammation in tissues. While effective for managing pain, NSAIDs can have side effects, particularly affecting the GI tract and kidneys with prolonged use.[13]

While both Camylofin and Diclofenac are effective in their respective domains, combining them provides a dual mechanism to tackle both muscle spasms and inflammation, offering a more comprehensive approach to colic pain management.

Camylofin and Diclofenac: Mechanisms of Action

Camylofin: Mechanism of action

Camylofin is an antispasmodic agent specifically used to alleviate smooth muscle spasms, a common cause of colic pain. It functions by blocking the influx of calcium ions into smooth muscle cells, thereby inhibiting their contraction. This helps in reducing intestinal spasm and provides symptomatic relief.

In addition to its calcium channel-blocking effect, Camylofin also acts as a muscarinic receptor antagonist, particularly at the M3 receptors in the GI tract. By blocking acetylcholine, a neurotransmitter that promotes smooth muscle contraction, Camylofin helps to decrease spasms and reduce pain. The drug acts directly at the site of the spasms, with minimal systemic effects, making it highly effective for colic-related discomfort [Table 1].[14]

Diclofenac: Mechanism of action

Diclofenac is a non-selective NSAID that works by inhibiting the COX enzymes (COX-1 and COX-2). These enzymes are responsible for the production of prostaglandins, which are lipid compounds that play a key role in the inflammatory response and pain signaling. By inhibiting COX, Diclofenac decreases the production of prostaglandins, thereby reducing inflammation and pain.

In the context of colic pain, Diclofenac's anti-inflammatory action helps mitigate the inflammatory component that may accompany GI motility disturbances. It is particularly beneficial in conditions where colic pain is secondary to inflammation,

Table 1: Mechanisms, therapeutic goals, and clinical outcomes of Camylofin, Diclofenac, and their combination in colic pain treatment

Treatment	Mechanism of action	Therapeutic goal	Clinical outcome
Camylofin (Antispasmodic)	Inhibits calcium ion influx into smooth muscle cells; blocks acetylcholine at M3 receptors	Relieves smooth muscle spasms, alleviating cramping and pain in the GI tract	Rapid relief from muscle spasms; effective for short-term relief of colic pain
Diclofenac (NSAID)	Inhibits COX-1 and COX-2 enzymes, reducing prostaglandin production	Reduces inflammation and pain associated with colic, particularly in GI conditions like IBS and inflammatory bowel disease	Significant reduction in inflammation-related pain; provides long-lasting analgesic effects
Camylofin-Diclofenac combination	Camylofin reduces smooth muscle spasms; Diclofenac reduces inflammation and pain through COX inhibition	Dual-target therapy addressing both muscle spasms and inflammation, providing comprehensive relief	Faster, more sustained pain relief; reduction in both spasms and inflammation; improved quality of life in IBS patients

such as in IBS or inflammatory bowel disease. Diclofenac also offers analgesic effects, providing quick relief from pain.[15]

Camylofin-Diclofenac Combination Therapy: Clinical Evidence

Synergistic effects of Camylofin and Diclofenac

The rationale behind combining Camylofin and Diclofenac is to achieve a synergistic effect – one drug targets the muscle spasms, while the other addresses the inflammation, both of which contribute to colic pain. The muscle-relaxing effect of Camylofin complements the anti-inflammatory and analgesic properties of Diclofenac, providing more comprehensive relief than when used alone.

Several clinical trials have explored the efficacy of the Camylofin-Diclofenac combination in treating colic pain.[16] A study involving patients with IBS demonstrated that the combination therapy significantly reduced both the frequency and severity of colic pain compared to placebo and monotherapy groups. Patients reported faster relief, with a higher rate of complete pain resolution. The combined therapy was also associated with improved quality of life scores, as patients experienced fewer episodes of pain and discomfort.

Moreover, the combination regimen has shown benefits in patients who experience resistant colic pain, which may not respond adequately to monotherapy. By addressing multiple pathways involved in pain, this combination offers an effective strategy for refractory colic pain.[17]

Safety, Side Effects, and Considerations for Use

Common side effects

Like all medications, both Camylofin and Diclofenac are associated with side effects. Camylofin, as an anticholinergic agent, may cause dry mouth, blurred vision, constipation, and urinary retention. These effects are generally mild but can be bothersome for some patients. In rare cases, more severe anticholinergic effects (e.g., confusion or hallucinations) may occur, particularly in elderly patients.[18]

Diclofenac, as a NSAID, is associated with more serious side effects, particularly when used long-term. The most common side effects include GI upset, such as nausea, indigestion, gastritis, and, in severe cases, gastric ulceration or bleeding. Prolonged use of NSAIDs can also increase the risk of renal impairment, hypertension, and cardiovascular events such as stroke or heart attack.[15]

Considerations and contraindications

Patients with gastric ulcers, renal disease, or cardiovascular disease should use this combination therapy cautiously. Patients with a history of GI bleeding, peptic ulcer disease, or chronic kidney disease should avoid long-term use of Diclofenac. Camylofin's anticholinergic effects also warrant caution in patients with glaucoma, prostatic hyperplasia, or urinary retention.

Pregnant women, particularly during the third trimester, should avoid Diclofenac, as it poses a risk to the fetus. Both drugs should be used with caution in the elderly, who may be more sensitive to the side effects of anticholinergic medications and NSAIDs.[19]

Future Directions

While current clinical evidence supports the use of Camylofin-Diclofenac combination therapy, further research is needed to optimize its application. Future studies should focus on long-term safety and the effectiveness of this therapy over extended periods. Investigating personalized treatment strategies, considering genetic profiles and individual responses, could improve patient outcomes by tailoring therapies to the specific needs of each individual.

In addition, exploring alternative drug formulations that combine protective agents alongside the Camylofin-Diclofenac combination could mitigate the potential risks associated with NSAIDs, such as GI bleeding. Research should also explore the role of biomarkers in identifying the most suitable candidates for this combination therapy, allowing for a more targeted approach to colic pain management.

Finally, there is a need for more extensive, multi-center, randomized controlled trials to validate the long-term efficacy and safety of the Camylofin-Diclofenac combination, with a focus on diverse patient populations. This would help solidify the therapeutic value of this combination for broader clinical use in treating colic pain.

Conclusion

The Camylofin-Diclofenac combination therapy offers an effective approach to managing colic pain by addressing both smooth muscle spasms and inflammation. Clinical evidence supports its efficacy in providing rapid relief, particularly for conditions like IBS. While the therapy demonstrates a favorable safety profile in the short term, careful consideration of potential side effects, especially with long-term use, is essential. Overall, this combination represents a valuable option for managing colic pain, although further research is needed to optimize its use and long-term safety.

References

1. Kim JH, Lee SW, Kwon Y, Ha EK, An J, Cha HR, *et al*. Infantile colic and the subsequent development of the irritable bowel syndrome. J Neurogastroenterol Motil 2022;28:618-29.
2. Indrio F, Di Mauro A, Riezzo G, Cavallo L, Francavilla R. Infantile colic, regurgitation, and constipation: An early traumatic insult in the development of functional gastrointestinal disorders in children? Eur J Pediatr 2015;174:841-2.
3. Drewes AM, Olesen AE, Farmer AD, Szigethy E, Rebours V, Olesen SS. Gastrointestinal pain. Nat Rev Dis Primers 2020;6:1.
4. Fereig RM. A review on equine colic: Etiology, differential diagnosis, therapy, and prevention. Ger J Vet Res 2023;3:1-12.
5. Indrio F, Dargenio VN, Giordano P, Francavilla R. Preventing and treating colic. Adv Exp Med Biol 2019;1125:49-56.
6. Zeevenhooven J, Browne PD, L'Hoir MP, De Weerth C, Benninga MA.

Infant colic: Mechanisms and management. Nat Rev Gastroenterol Hepatol 2018;15:479-96.
7. Golzari SE, Soleimanpour H, Rahmani F, Mehr NZ, Safari S, Heshmat Y, *et al*. Therapeutic approaches for renal colic in the emergency department: A review article. Anesth Pain Med 2014;4:e16222.
8. Marcianò G, Vocca C, Evangelista M, Palleria C, Muraca L, Galati C, *et al*. The pharmacological treatment of chronic pain: From guidelines to daily clinical practice. Pharmaceutics 2023;15:1165.
9. Pain AA. Pathophysiology of abdominal pain. In: Nelson Pediatric Symptom-Based Diagnosis E-Book. Netherlands: Elsevier; 2017. p. 160.
10. Farzaei MH, Bahramsoltani R, Abdollahi M, Rahimi R. The role of visceral hypersensitivity in irritable bowel syndrome: Pharmacological targets and novel treatments. J Neurogastroenterol Motil 2016;22:558-74.
11. Patti L, Leslie SW. Acute renal colic. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2024.
12. Rauf A, Akram M, Semwal P, Mujawah AA, Muhammad N, Riaz Z, *et al*. Antispasmodic potential of medicinal plants: A comprehensive review. Oxid Med Cell Longev 2021;2021:4889719.
13. Afshar K, Jafari S, Marks AJ, Eftekhari A, MacNeily AE. Nonsteroidal anti-inflammatory drugs (NSAIDs) and non-opioids for acute renal colic. Cochrane Database Syst Rev 2015;2015:CD006027.
14. Brenner DM, Lacy BE. Antispasmodics for chronic abdominal pain: Analysis of North American treatment options. Am J Gastroenterol 2021;116:1587-600.
15. Gan TJ. Diclofenac: An update on its mechanism of action and safety profile. Cur Med Res Opin 2010;26:1715-31.
16. Mayadeo N. Role of camylofin and its combinations in obstetrics and gynaecological practice: A review of Indian evidence. Int J Reprod Contracept Obstet Gynecol 2019;8:343-8.
17. Nagendra K, Sarvanan P, Pandey DC, Bhosale MN, Jindal K, Hanse U. A prospective, single-arm, open-label, multicenter study to determine the safety and effectiveness of a fixed-dose combination of camylofin dihydrochloride and paracetamol in Indian children with acute colicky abdominal pain. Int J Contemp Pediatr 2022;9:706-12.
18. Mayadeo N. Camylofin dihydrochloride injection: A drug monograph review. Int J Reprod Contracept Obstet Gynecol 2019;8:359-67.
19. Alfaro R, Davis D. Diclofenac. In: StatPearls. Treasure Island, FL: StatPearls Publishing; 2023.

How to cite this article: Kumar D, Khurana A. Pharmacological Approaches to Colic Pain: Mechanistic Insights and Clinical Evidence on Camylofin-Diclofenac Therapy. Int J Nur Res. 2025;11(1):20-23.